– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq ...

Core Insights - Genmab A/S announced promising results from the Phase 1b/2 EPCORE NHL-2 trial, demonstrating the efficacy of epcoritamab in combination with R-ICE for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) [2][4][5] Trial Results - The overall response rate (ORR) was reported at 87 percent, with a complete response (CR) rate of 65 percent and a partial response (PR) rate of 23 percent [2][6] - At six months, 81 percent of responses were ongoing, 74 percent of patients were progression-free, and 100 percent of patients were alive [2][6] - Among patients who progressed within 12 months after first-line treatment, the ORR was 85 percent and the CR rate was 55 percent [4] - For patients who progressed after 12 months from first-line therapy, the ORR was 91 percent and the CR rate was 82 percent [4] Safety Profile - The safety profile indicated low-grade cytokine release syndrome (CRS) with no treatment discontinuations due to treatment-emergent adverse events (TEAEs) [3][5] - The most common TEAEs included neutropenia (74 percent), anemia (68 percent), and thrombocytopenia (68 percent) [3] - Serious infections were reported in 16 percent of patients, with no Grade 5 TEAEs observed [3] Industry Context - DLBCL accounts for approximately 25-30 percent of all non-Hodgkin's lymphoma cases globally, with around 25,000 new cases diagnosed annually in the U.S. [6][7] - The investigational treatment with epcoritamab aims to address significant unmet needs in the management of R/R DLBCL and other hematologic malignancies [5][12] Future Development - Genmab is collaborating with AbbVie to further develop epcoritamab as a core therapy for B-cell lymphomas, with ongoing trials evaluating its use in various treatment lines [5][12] - The EPCORE NHL-2 trial is part of a broader clinical program aimed at advancing epcoritamab both as monotherapy and in combination therapies [8][12]

Core Viewpoint - Roche has implemented new dosing restrictions for Elevidys™ (delandistrogene moxeparvovec) for non-ambulatory Duchenne muscular dystrophy (DMD) patients due to two cases of fatal acute liver failure, leading to a reassessment of the benefit-risk profile as unfavorable for this patient group [1][2][4][7]. Group 1: Dosing Restrictions - Effective immediately, non-ambulatory patients will no longer receive Elevidys in commercial settings, and dosing for these patients in clinical trials is paused until additional risk mitigation measures are established [1][7]. - The new restrictions do not affect ambulatory DMD patients, where the benefit-risk ratio remains positive [2][7]. Group 2: Clinical Context - The two fatal cases of acute liver failure occurred among approximately 140 non-ambulatory patients treated with Elevidys globally [4]. - European regulators have requested temporary clinical holds on several Elevidys studies following the incidents [4]. Group 3: Product Overview - Elevidys is the first approved gene therapy for DMD, designed to deliver new instructions to cells to produce dystrophin, aiming to slow disease progression [10][11]. - The treatment has been approved in eight territories, including Bahrain, Brazil, and Japan, and Roche collaborates with Sarepta Therapeutics for its commercialization [5][11]. Group 4: Disease Background - Duchenne muscular dystrophy is a rare genetic disease primarily affecting males, with a prevalence of 1 in 5,000 boys born worldwide, leading to progressive muscle weakness and loss of mobility [3][12]. - The average life expectancy for individuals with Duchenne is only 28 years, highlighting the critical need for effective treatments [12][16].

Core Insights - Celldex Therapeutics announced that barzolvolimab significantly improves angioedema in chronic spontaneous urticaria (CSU) patients after 52 weeks of treatment [1][2][3] Group 1: Clinical Trial Results - The Phase 2 clinical trial met primary and secondary endpoints at 12 weeks, showing significant decreases in UAS7 scores compared to placebo [2][5] - At Week 52, an 86% mean reduction in angioedema activity was reported for the 150 mg Q4W group, and an 82% reduction for the 300 mg Q8W group [6] - 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema-free at Week 52 [5][6] Group 2: Patient Impact - The majority of patients with severe CSU experience painful angioedema, which significantly affects their quality of life [3][6] - 87% of patients reported clinically meaningful improvement in angioedema activity scores at Week 52 [6] Group 3: Drug Mechanism and Future Studies - Barzolvolimab is a humanized monoclonal antibody that targets the receptor tyrosine kinase KIT, which is involved in mast cell activation [4] - Celldex is conducting a global Phase 3 program for barzolvolimab in CSU, with enrollment currently underway [8]

Core Insights - Jasper Therapeutics, Inc. presented promising data from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study, showing that 100% of participants achieved a clinical response and 92% achieved a complete response [1][2][5] - The study demonstrated rapid and durable efficacy, with significant improvements observed as early as week 1, and 66% of participants achieving clinical response by week 2 [1][5][10] - Briquilimab was well tolerated, with no serious adverse events reported in the 180mg cohort, indicating a potentially differentiated safety profile [1][9][10] Study Design and Results - The SPOTLIGHT study is an open-label clinical trial evaluating briquilimab in adult participants with cold urticaria or symptomatic dermographism who are refractory to antihistamines, enrolling 27 participants across three dose cohorts: 40mg, 120mg, and 180mg [3][4] - Among the 12 participants in the 180mg cohort, 25% were diagnosed with cold urticaria and 75% with symptomatic dermographism, with a high disease burden indicated by provocation threshold testing [4][5] - Overall, 81% of participants in the study achieved a complete response, and 96% achieved either a complete or partial response [6][7] Safety and Tolerability - The mean baseline serum tryptase for the 180mg cohort was 5.1 ng/ml, with significant reductions observed, correlating with clinical responses [8] - No serious adverse events or grade 3 or higher adverse events were reported, with mild, transient drops in neutrophil counts observed in some participants [9][10] - The safety profile of briquilimab appears favorable, with low frequency and low-grade adverse events that resolved quickly [10] Company Information - Jasper Therapeutics is focused on developing briquilimab as a therapeutic for chronic mast cell diseases, including chronic spontaneous urticaria and asthma [13] - The company is conducting clinical studies to further evaluate briquilimab's efficacy and safety profile in patients with chronic urticaria and asthma [13]

Group 1 - The Company declared a quarterly cash dividend of $0.125 per share of common stock and Operating Partnership unit for the quarter ended June 30, 2025, payable on July 31, 2025 [1] - The Company announced a dividend of $0.390625 per share of its 6.25% Series C Cumulative Convertible Preferred Stock, payable on July 15, 2025 [2] - A dividend of $0.40625 per share of its 6.50% Series E Cumulative Redeemable Preferred Stock was also declared, payable on July 31, 2025 [3] Group 2 - Ready Capital Corporation is a multi-strategy real estate finance company that originates, acquires, finances, and services lower-to-middle-market investor and owner-occupied commercial real estate loans [4] - The Company specializes in loans backed by commercial real estate, including agency multifamily, investor, construction, and bridge loans, as well as U.S. Small Business Administration loans under its Section 7(a) program [4] - The Company is headquartered in New York and employs approximately 500 professionals nationwide [4]

Core Insights - KOORUI has launched the 34E6UC, a 34-inch ultra-wide curved display aimed at enhancing productivity and entertainment experiences [1][3] - The demand for ultra-wide monitors has increased by over 15% year-over-year, driven by professionals, gamers, and digital creators [3] Product Features - The 34E6UC features a 3440×1440 WQHD resolution and a 1000R curved screen, providing an immersive viewing experience suitable for both cinematic entertainment and multitasking [4] - It boasts a 180Hz refresh rate and 1ms MPRT, ensuring smooth visuals and minimal motion blur, which is particularly beneficial for fast-paced gaming [5] - The monitor covers 90% of the DCI-P3 and 125% of the sRGB color gamuts, offering professional-grade color accuracy for creative professionals [6] Market Positioning - The 34E6UC is positioned as a versatile solution for both productivity and entertainment, catering to a wide range of users from professionals to gamers [7] - It is available on Amazon US and highlighted as a key pick for Prime Day 2025, emphasizing its competitive value [7] Company Background - KOORUI is powered by HKC's semiconductor display expertise, focusing on innovative panel manufacturing and human-centered design [9]

Company Overview - Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care [5] - The company's flagship offering, HealthTab™, aims to create the world's largest network of rapid testing devices in community pharmacies [5] Stock Options Announcement - The board of directors of Avricore has approved the granting of stock options for a total of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1] - The options will vest quarterly starting from the date of grant and will expire 5 years from the grant date, contingent on the optionees remaining in their roles [2] HealthTab™ Product Details - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, with real-time data reporting [3] - The test menu includes up to 23 key biomarkers for chronic disease management, including diabetes and heart disease, and has recently added capabilities for bacterial and viral tests [3] HealthTab™ Network Model - The HealthTab™ network model enhances the role of pharmacists in primary care delivery and empowers patients to take control of their health [4] - It aims to reduce costs and waiting times while providing multiple revenue streams, including equipment leasing, direct access testing, and decentralized clinical trials [4]

Group 1 - The 30th Guangzhou International Lighting Exhibition (GILE) took place from June 9 to 12, 2025, featuring over 3,000 exhibitors and focusing on the theme "AI + 3D Printing: Pioneering a New Era of Lighting" [1] - YD Illumination showcased a 200+ square-meter double-decker exhibition hall, highlighting its latest innovations in lighting and AI-powered 3D printing [1][5] - The exhibition included immersive simulations demonstrating the durability of YD Illumination's IP68 lighting products in various harsh environments [3] Group 2 - A notable exhibit was the IP68 Flexible Strip Light Series, which won the Aladdin Golden Lamp Award for National Excellence, alongside the Mini Master-sub controller [3] - An interactive "Mermaid" installation was created using AI-generated 3D modeling and precision 3D printing, allowing real-time human-light interactions [4] - The exhibition featured an AI + 3D Printing Experience Zone where visitors could generate 3D models from text descriptions or images, followed by live demonstrations of the printing process [4] Group 3 - YD Illumination is committed to technological innovation and aims to deliver groundbreaking solutions while exploring the possibilities of light [5]

Core Points - Aetherium Acquisition has postponed its Special Meeting to June 27, 2025, with the redemption right deadline now set for June 25, 2025 [1][2] - The record date for the Meeting remains May 9, 2025, and no changes have been made to the proposals for shareholder voting [2] - Aetherium Acquisition is a blank check company focused on mergers and acquisitions, particularly targeting companies in Asia (excluding China) [4] Proxy Statement and Solicitation - The Company filed a definitive proxy statement with the SEC on May 23, 2025, and a revised statement on June 3, 2025, urging shareholders to read these documents carefully [3] - The Company and its management may be deemed participants in the solicitation of proxies from shareholders for the Meeting [6]